Core Viewpoint - The A-share market is entering a period of intensive new stock offerings, with five companies available for subscription this week from October 13 to October 17, including Marco Polo, Chao Ying Electronics, He Yuan Bio, Xi'an Yicai, and Biobetter [1] Group 1: Marco Polo - Marco Polo is one of the largest manufacturers and sellers of building ceramics in China, with major brands including "Marco Polo Tiles" and "Weimei L&D Ceramics" [2] - The company has five production bases located in Dongguan, Qingyuan, Fengcheng, Chongqing, and Tennessee, USA, focusing on glazed and unglazed tiles [2] - For the fiscal years 2022 to 2024, Marco Polo's revenue is projected to be 8.661 billion, 8.925 billion, and 7.324 billion yuan, with net profits of 1.514 billion, 1.353 billion, and 1.327 billion yuan respectively [2] - The funds raised will be used for various smart manufacturing upgrades and capacity enhancement projects [2] Group 2: He Yuan Bio - He Yuan Bio is an innovative biopharmaceutical company that has developed a leading rice recombinant protein expression system [3] - The company has achieved a human albumin expression level of 20-30g/kg using its OryzHiExp third-generation technology platform [3] - Revenue projections for 2022 to 2024 are 13 million, 24 million, and 25 million yuan, with net losses of 144 million, 187 million, and 151 million yuan respectively [3][4] - The raised funds will be allocated to the construction of an industrial base for recombinant human albumin and new drug development projects [4] Group 3: Chao Ying Electronics - Chao Ying Electronics specializes in the research, production, and sales of printed circuit boards (PCBs), with applications in automotive electronics, displays, storage, and consumer electronics [5] - The company has established stable partnerships with major global automotive suppliers and display panel manufacturers [6] - Revenue for 2022 to 2024 is expected to be 3.514 billion, 3.656 billion, and 4.124 billion yuan, with net profits of 141 million, 266 million, and 276 million yuan respectively [6] - The funds raised will be used for high-layer and HDI project investments and to repay bank loans [6] Group 4: Xi'an Yicai - Xi'an Yicai focuses on the research, production, and sales of 12-inch silicon wafers, ranking first in mainland China and sixth globally [7] - The company has the highest number of authorized domestic and foreign invention patents in the 12-inch silicon wafer sector in mainland China [7] - Revenue projections for 2022 to 2024 are 1.055 billion, 1.474 billion, and 2.121 billion yuan, with net losses of 412 million, 578 million, and 738 million yuan respectively [7][8] - The raised funds will be fully invested in the second phase of the Xi'an Yiswei silicon industry base project [8] Group 5: Biobetter - Biobetter is a biopharmaceutical company focused on innovative drug development for major diseases, including cancer and autoimmune diseases [9] - The company has several products in various stages of clinical trials, with its core product BEBT-908 already approved for market [9][10] - Revenue projections for 2022 to 2024 indicate net losses of 188 million, 173 million, and 56 million yuan respectively [10] - The funds raised will be used for new drug development and the establishment of a research center and formulation industrialization base [11]

Core Viewpoint - The article discusses the upcoming IPOs in the A-share market, highlighting five companies that will be available for subscription this week, emphasizing their business focus and financial performance. Group 1: Upcoming IPOs - This week (October 13-17), there will be five new stocks available for subscription in the A-share market, including Marco Polo, Chao Ying Electronics, He Yuan Bio, Xi'an Yicai, and Biobetter [1] - Marco Polo is one of the largest manufacturers and sellers of building ceramics in China, with an IPO price of 13.75 CNY per share and a subscription limit of 32,000 shares per account [1][2] - He Yuan Bio is an innovative biopharmaceutical company with a subscription limit of 14,000 shares per account, focusing on recombinant human albumin production [3][4] - Chao Ying Electronics specializes in automotive electronic PCBs, with a subscription limit of 12,500 shares per account [5][7] - Xi'an Yicai is a leading manufacturer of 12-inch silicon wafers, with a subscription limit of 53,500 shares per account [8][9] - Biobetter focuses on innovative drug development for major diseases, with a subscription limit of 14,000 shares per account [10][12] Group 2: Financial Performance - Marco Polo's projected revenues for 2022-2024 are 8.661 billion CNY, 8.925 billion CNY, and 7.324 billion CNY, with net profits of 1.514 billion CNY, 1.353 billion CNY, and 1.327 billion CNY respectively [2] - He Yuan Bio's projected revenues for 2022-2024 are 0.13 billion CNY, 0.24 billion CNY, and 0.25 billion CNY, with net losses of 1.44 billion CNY, 1.87 billion CNY, and 1.51 billion CNY [3][4] - Chao Ying Electronics' projected revenues for 2022-2024 are 3.514 billion CNY, 3.656 billion CNY, and 4.124 billion CNY, with net profits of 0.141 billion CNY, 0.266 billion CNY, and 0.276 billion CNY [6][7] - Xi'an Yicai's projected revenues for 2022-2024 are 1.055 billion CNY, 1.474 billion CNY, and 2.121 billion CNY, with net losses of 0.412 billion CNY, 0.578 billion CNY, and 0.738 billion CNY [8][9] - Biobetter's projected net losses for 2022-2024 are 0.188 billion CNY, 0.173 billion CNY, and 0.056 billion CNY [10][11]

Market Overview - On October 10, 2025, the A-share market saw all three major indices decline, with the Shanghai Composite Index closing at 3897.03 points, down 0.94%, and the Shenzhen Component Index down 2.7% at 13355.42 points. The ChiNext Index fell 4.55% to 3113.26 points. Despite the overall decline, over 2700 stocks rose, with total trading volume in the Shanghai and Shenzhen markets at 2.52 trillion yuan, a decrease of 130 billion yuan from the previous trading day [1] - The Hong Kong stock market also experienced declines, with the Hang Seng Index dropping 1.73% to 26290.32 points, marking five consecutive days of losses. The total trading volume was 333.74 billion HKD, with the Hang Seng China Enterprises Index down 1.8% and the Hang Seng Tech Index down 3.27%. For the week, the Hang Seng Index fell 3.13% [1] - In the U.S. market, major indices faced significant drops due to comments from President Trump and a government shutdown crisis, with the Dow Jones falling 1.9%, the Nasdaq plummeting 3.56%, and the S&P 500 down 2.71%. All three indices recorded weekly declines exceeding 2.4% [1] New Stock Subscription - A new stock, Marco Polo (stock code 001386), is available for subscription at an issuance price of 13.75 yuan per share, with a price-to-earnings ratio of 14.27. The company is a leading manufacturer and seller of building ceramics in China, with major brands including "Marco Polo Tiles" and "Weimei L&D Ceramics." It operates five production bases in China and the U.S., offering a comprehensive range of products including glazed and unglazed tiles [2] Important News - On October 11, 2025, the Shanghai Municipal Government issued measures to accelerate the innovation of frontier technologies and the cultivation of future industries. The measures focus on six key development areas: future manufacturing, future information, future materials, future energy, future space, and future health. The plan includes support for reducing costs and improving accessibility in fields like cell and gene therapy, brain-machine interfaces, and biological manufacturing [2] Regulatory Actions - The China Securities Regulatory Commission (CSRC) announced administrative penalties against *ST Yuancheng for serious financial fraud, proposing a fine of 37.45 million yuan for the company and a total of 42 million yuan for five responsible individuals. The company was found to have inflated revenue and profits for three consecutive years, violating securities laws. The CSRC will initiate delisting procedures due to significant violations, and potential criminal evidence will be referred to law enforcement [4]

Core Viewpoint - The company Marco Polo is a leading player in the domestic ceramic tile industry, with a strong brand value and a focus on expanding into related home furnishing products and innovative new offerings [2][3]. Group 1: Company Overview - The company is listed on the Shenzhen Main Board with the stock code 001386 and has an issuance price of 13.75 yuan [2]. - The total market capitalization of the company is 14.79 billion yuan, with an industry P/E ratio of 14.27 [2]. - The main business composition includes 98.14% glazed tiles and 1.86% unglazed tiles [2]. Group 2: Financial Performance - The company reported revenues of 7.324 billion yuan in 2024, reflecting a decrease of 17.93% compared to the previous year [3]. - The net profit attributable to the parent company was 8.925 billion yuan in 2023, showing an increase of 3.05% from 2022, which had a net profit of 8.661 billion yuan, down by 7.52% [3]. Group 3: Business Highlights and Future Plans - The company is gradually expanding into finished furniture and related home scenarios while actively developing new products, including curved electric ceramic tiles and 2.5mm ultra-thin high-strength decorative ceramic slabs [2]. - The fundraising will be directed towards upgrading the intelligent ceramic home industry park and green intelligent manufacturing projects in Jiangxi and Guangdong [3].

Group 1: New IPOs and Market Overview - This week (October 13 to 17), there are 5 new stocks available for subscription, including 1 from the Shanghai Main Board, 1 from the Shenzhen Main Board, and 3 from the Sci-Tech Innovation Board [1][2] - Xi'an Yicai ranks second in total shares issued among new stocks in the Shanghai and Shenzhen markets since 2025, indicating a potentially high probability of winning the subscription [1] - Marco Polo, a new stock on the Shenzhen Main Board, has an issue price of 13.75 yuan and a price-to-earnings ratio of 14.27, compared to the industry average of 28.02 [2] Group 2: Company Profiles and Financials - He Yuan Bio, launching on October 14, focuses on plant-based recombinant protein technology and has 8 products in development or on the market. Its core product, HY1001, is the first recombinant human albumin drug approved in China, addressing a market size of approximately 30% of human serum albumin [1][3] - Marco Polo is the largest manufacturer and seller of building ceramics in China, with a total fundraising amount of 1.643 billion yuan from its IPO [2] - Xi'an Yicai, a leading supplier of 12-inch silicon wafers, aims to raise 4.9 billion yuan through its IPO [4] - Biotech company Bibet focuses on innovative drug development for major diseases and plans to raise 2.005 billion yuan in its IPO [4] Group 3: Upcoming IPO Meetings - Three companies are scheduled for IPO meetings this week: Youxun Co. and Angrui Micro on the Sci-Tech Innovation Board, and Tian Su Measurement on the Growth Enterprise Market [5][6] - Youxun Co. specializes in optical communication chips and aims to raise 809 million yuan [6] - Angrui Micro focuses on RF and analog integrated circuit design, with a planned fundraising of 2.067 billion yuan [6] - Tian Su Measurement provides third-party measurement and testing services, targeting a fundraising of 424 million yuan [6]

Group 1 - The People's Bank of China will have a total of 10,210 billion yuan in reverse repos maturing this week [1] - China Life Insurance will distribute a total cash dividend of 6.727 billion yuan (including tax) for the semi-annual A-share profit distribution, with the record date on October 16 and payment date on October 17 [1] - Leading magnetic material company, Yuedong East Magnetic, expects a net profit growth of 50.1% to 65.2% year-on-year for the first three quarters [1] Group 2 - The China Foreign Exchange Trading Center has optimized the "Swap Connect" operating mechanism, increasing the daily net limit to 45 billion yuan starting today [2] Group 3 - A new round of adjustments to domestic retail prices for refined oil will take place at 24:00 today [3]

Core Viewpoint - The new stock market remains active post-National Day holiday, with significant IPO activity and investor enthusiasm, particularly in the Beijing Stock Exchange, highlighted by the debut of Aomeisen, which surged 349.82% on its first day [1]. Group 1: New Stock Listings - A total of 15 companies have completed listings on the Beijing Stock Exchange by September 2025, raising 4.9 billion yuan, indicating an accelerated IPO pace [1]. - Next week, five new stocks will be available for subscription, including Chaoying Electronics, a major global supplier of automotive electronic PCBs, and Xian Yicai, the largest 12-inch silicon wafer manufacturer in mainland China [1][2][4]. Group 2: Company Profiles - **Chaoying Electronics**: Established for over 20 years, the company has a diverse product matrix in the automotive electronic PCB sector, collaborating with major global automotive suppliers and brands [1]. - **Xian Yicai**: Ranked first in mainland China and sixth globally in 12-inch silicon wafer production, the company supplies major semiconductor manufacturers and is actively developing high-end storage chips for AI applications [2][11]. - **Marco Polo**: A leading manufacturer of building ceramics in China, the company anticipates a net profit of 1 billion to 1.05 billion yuan for the first three quarters of 2025, reflecting a year-on-year decline of 12.06% to 7.66% [6][8]. - **He Yuan Biology**: An innovative biopharmaceutical company focusing on plant-based bioreactor technology, currently in the R&D phase with no profits yet [8]. - **Bibeite**: A biopharmaceutical firm focused on innovative drug development for major diseases, with its core product already approved for market [13].

Group 1: New IPOs and Subscription Information - Five new stocks are available for subscription next week, with one stock available for each trading day [2] - Marco Polo's subscription code is 001386, with an issue price of 13.75 yuan per share and an issuance PE ratio of 14.27 times [4] - He Yuan Bio's subscription code is 787765, with a total issuance of 89.45 million shares [8] - Chao Ying Electronics' subscription code is 732175, with a total issuance of 52.5 million shares [12][13] - Xi'an Yicai's subscription code is 787783, with a total issuance of 538 million shares [18] - Biobetter's subscription code is 787759, with a total issuance of 90 million shares [24] Group 2: Company Performance and Financials - Marco Polo is the leading company in China's architectural ceramics industry, with projected revenues of 86.61 billion yuan in 2022, 89.25 billion yuan in 2023, and 73.24 billion yuan in 2024 [4] - He Yuan Bio's revenue for 2022 to 2024 is projected to be 13.39 million yuan, 24.26 million yuan, and 25.22 million yuan respectively, with net losses of 144 million yuan, 187 million yuan, and 151 million yuan [8][10] - Chao Ying Electronics' revenue for 2022 to 2024 is projected to be 3.514 billion yuan, 3.656 billion yuan, and 4.124 billion yuan, with net profits of 141 million yuan, 266 million yuan, and 276 million yuan [13] - Xi'an Yicai's revenue for 2022 to 2024 is projected to be 1.055 billion yuan, 1.474 billion yuan, and 2.121 billion yuan, with net losses of 412 million yuan, 578 million yuan, and 738 million yuan [18] - Biobetter's projected net losses for 2022 to 2024 are 188 million yuan, 173 million yuan, and 56 million yuan [24] Group 3: Market Position and Competitive Landscape - Marco Polo is positioned in the first tier of the architectural ceramics industry, competing with companies like Dongpeng Holdings and Mona Lisa [4] - He Yuan Bio focuses on innovative biopharmaceuticals, with its core product HY1001 being the first recombinant human albumin drug approved in China [8] - Chao Ying Electronics is among the top ten global automotive electronic PCB suppliers and one of the top five in China [13] - Xi'an Yicai is ranked as the number one manufacturer of 12-inch silicon wafers in mainland China and sixth globally [18] - Biobetter is focused on developing first-in-class drugs for major diseases, with significant ongoing R&D investments [24][27]

Summary of Upcoming IPOs - Next week, there will be 5 new stock subscriptions, including 2 from the main board and 3 from the Sci-Tech Innovation Board [1] - Each trading day next week will feature one new stock subscription, with higher subscription rates expected for Marco Polo and Xi'an Yicai due to their larger issuance volumes [1] Company Profiles Marco Polo - Marco Polo is a leading company in the domestic building ceramics industry, with an issuance price of 13.75 CNY per share and a price-to-earnings ratio of 14.27, compared to the industry average of 32.2 [2][3] - The company plans to issue 11,949,200 shares, with a maximum subscription limit of 32,000 shares, requiring a market value of 320,000 CNY in the Shenzhen market [2] - Revenue projections for Marco Polo are 8.661 billion CNY in 2022, 8.925 billion CNY in 2023, and 7.324 billion CNY in 2024, with net profits of 1.514 billion CNY, 1.353 billion CNY, and 1.327 billion CNY respectively [3] He Yuan Bio - He Yuan Bio is an innovative biopharmaceutical company focused on plant-derived recombinant protein expression technology [4][5] - The company plans to issue 8,945,140 shares, with a maximum subscription limit of 14,000 shares, requiring a market value of 140,000 CNY in the Shanghai market [5] - He Yuan Bio's innovative drug, recombinant human albumin injection (rice), was approved for market in July [5] Chao Ying Electronics - Chao Ying Electronics is a core supplier of automotive electronic PCBs, ranking among the top ten globally and top five in China [7][8] - The company plans to issue 52,500,000 shares, with a maximum subscription limit of 12,500 shares, requiring a market value of 125,000 CNY in the Shanghai market [8] - Revenue projections for Chao Ying Electronics are 3.514 billion CNY in 2022, 3.656 billion CNY in 2023, and 4.124 billion CNY in 2024, with net profits of 141 million CNY, 266 million CNY, and 276 million CNY respectively [8] Xi'an Yicai - Xi'an Yicai is a leading domestic semiconductor materials company, with the second-largest issuance volume among new stocks this year [9][10] - The company plans to issue 53,780,000 shares, with a maximum subscription limit of 53,500 shares, requiring a market value of 535,000 CNY in the Shanghai market [10] - Xi'an Yicai is the largest supplier of 12-inch silicon wafers to major domestic logic wafer foundries and has a significant market presence [11] Biobetter - Biobetter focuses on the independent research and development of innovative drugs, particularly in oncology and autoimmune diseases [12][13] - The company plans to issue 90,000,000 shares, with a maximum subscription limit of 14,000 shares, requiring a market value of 140,000 CNY in the Shanghai market [13] - Biobetter's core product, BEBT-908, has been approved for market, while other products are still in development [13]

Core Points - Guangdong Dongpeng Holdings Co., Ltd. has recently obtained 13 invention patent certificates from the National Intellectual Property Administration [1] - The company and its subsidiaries have a total of 2,525 patents, with 1,315 valid patents, including 431 invention patents [1] - The newly acquired patents are related to building ceramics technology or equipment and are directly linked to the company's core technologies [1] - The patents have a validity period of 20 years from the date of application [1] - The acquisition of these patents enhances the company's ability to protect its intellectual property, prevents infringement, and strengthens its competitive position in the market [1] Summary by Category Patent Acquisition - The company has obtained 13 new invention patents, increasing its total patent count to 2,525 [1] - Out of the total, there are 1,315 valid patents, including 431 invention patents [1] Application and Relevance - The new patents are applicable in the field of building ceramics technology or equipment and are already in use or will soon be applied in the company's production [1] Strategic Importance - The patents help the company protect its intellectual property, prevent infringement, and maintain a competitive edge in the market [1] - This development supports the company's ongoing innovation capabilities and enhances its brand and market influence [1]